Increased renal versican expression is associated with progression of chronic kidney disease

• Published in: PloS one 2012-09, Vol.7 (9), p.e44891-e44891
• Main Authors: Rudnicki, Michael, Perco, Paul, Neuwirt, Hannes, Noppert, Susie-Jane, Leierer, Johannes, Sunzenauer, Judith, Eder, Susanne, Zoja, Carlamaria, Eller, Kathrin, Rosenkranz, Alexander R, Müller, Gerhard A, Mayer, Bernd, Mayer, Gert
• Format: Article
• Language: English
• Subjects: Animal models; Animals; Apoptosis; Biology; Biomarkers; Biomarkers - metabolism; Biopsy; Care and treatment; Cell growth; Cell Line; Chemokines; Chronic kidney failure; Creatinine; Development and progression; Diabetes; Diabetes mellitus; Diabetic nephropathies; Disease Models, Animal; Disease Progression; Fibroblasts; Fibroblasts - metabolism; Gene expression; Gene Expression Regulation; Hemodialysis; Histology; Humans; Hypertension; Hypoxia; Internal medicine; Isoforms; Kidney - pathology; Kidney - physiopathology; Kidney diseases; Kidney Tubules, Proximal - metabolism; Kidney Tubules, Proximal - pathology; Kidneys; Medical prognosis; Medical research; Medicine; Mice; Nephrology; Nephropathy; Parameters; Patients; Physiology; Prognosis; Prostate cancer; Proteins; Rats; Renal failure; Renal function; Renal Insufficiency, Chronic - metabolism; Renal Insufficiency, Chronic - pathology; Renal Insufficiency, Chronic - physiopathology; Ribonucleic acid; Risk Factors; RNA; RNA Isoforms - metabolism; Rodents; Transforming Growth Factor beta1 - metabolism; Vascular endothelial growth factor; Versican; Versicans - genetics; Versicans - metabolism
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0044891

Novel prognostic markers for progression of kidney disease are needed to distinguish patients who might benefit from a more aggressive nephroprotective therapy. Expression of the proteoglycan versican was evaluated in renal transcriptomics profiles and in an independent set of 74 renal biopsies. Versican levels were correlated to histologic damage scores and to renal outcome, and versican expression and regulation was evaluated in vitro. In transcriptomics profiles of renal tissue versican was positively correlated with (i) histological parameters in kidney biopsies, (ii) progressive decline of renal function in proteinuric kidney diseases, and (iii) impaired renal function and histology scores in diabetic nephropathy. In an independent cohort of 74 biopsies of glomerular diseases renal RNA levels of versican isoforms V0 and V1, but not V2 and V3 correlated significantly with creatinine after a mean follow up time of 53 months. Versican isoforms V0 and V1 together with serum creatinine at time of biopsy and the degree of glomerulosclerosis predicted 20% and 24% of the variability of creatinine at follow up, which was significantly more than serum creatinine and histological parameters alone (16%). However, when patients with acute kidney failure at time of biopsy (n = 5) were excluded, the additive predictive value of versican V1 was only marginally higher (35%) than creatinine and glomerulosclerosis alone (34%). Versican isoforms V0 and V1 were primarily expressed in vitro in proximal tubule cells and in fibroblasts. The results in humans were confirmed in three rodent models of kidney disease, in which renal versican expression was significantly upregulated as compared to corresponding controls. These data show for the first time an association of renal versican isoform V0 and V1 expression with progressive renal disease.